Companies: 10,795·Total market cap: $144.5T
Sera Prognostics, Inc.

Sera Prognostics, Inc.

SERANASDAQHealthcare● Active
$2.10
$-0.19(-8.30%)
Market Cap$80201029
P/E Ratio
52W High$4.09
52W Low$1.411
Overview

Sera Prognostics, Inc. (SERA) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

sera · pe ratio · data through Dec 31, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for Sera Prognostics, Inc. (SERA) measures how much investors pay for each dollar of the company's trailing earnings. SERA's current PE ratio of N/A is calculated by dividing its stock price of $2.10 by its TTM earnings per share of -$0.64.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31

Forward P/E
N/A
FY2027 est. EPS $-0.56
Based on 2 analysts
EPS (TTM)
-$0.64
TTM · diluted EPS
PEG Ratio
-0.08
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Sera Prognostics, Inc. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-09

PE Ratio History

2019 – 2025 · Annual
PE Ratio (TTM)
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Medical - Diagnostics & Research · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
Sera Prognostics, Inc.
Sera Prognostics, Inc.You
SERA
$80MN/A-$0.64
Apyx Medical Corporation
Apyx Medical Corporation
APYX
$200MN/A-$0.27
Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc.
ATOS
$39MN/A-$4.04
Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc.
CGTX
$89MN/A-$0.32
TuHURA Biosciences, Inc.
TuHURA Biosciences, Inc.
HURA
$130MN/A-$0.63
Lucid Diagnostics Inc.
Lucid Diagnostics Inc.
LUCD
$98MN/A-$0.57
Oncolytics Biotech Inc.
Oncolytics Biotech Inc.
ONCY
$84MN/A-$0.41

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 7 of 7 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2025-12-31Latest
FY2025
$-0.67
2024-12-31
FY2024
$-0.99
2023-12-31
FY2023
$-1.16
2022-12-31
FY2022
$-1.43
2021-12-31
FY2021
$-1.14
2020-12-31
FY2020
$-1.10
2019-12-31
FY2019
$-0.91

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for Sera Prognostics, Inc. (SERA) measures how much investors pay for each dollar of the company's trailing earnings. SERA's current PE ratio of N/A is calculated by dividing its stock price of $2.10 by its TTM earnings per share of -$0.64.

PE Ratio = Stock Price ÷ EPS (TTM)
= $2.10 ÷ -$0.64 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

SERA pe ratio · 6 questions

SERA's current PE ratio is N/A as of 2026-06-09, based on a stock price of $2.10 and TTM EPS of -$0.64. Data sourced from Financial Modeling Prep via SERA's SEC 10-K and 10-Q filings.

SERA PE ratioWhat is SERA PE ratioCurrent PE ratio of SERASERA PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Sera Prognostics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09